Genotyping of a family with a novel deleteriousDPYDmutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio-Reference-Cited by-同舟云学术

Genotyping of a family with a novel deleteriousDPYDmutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio

Published:2015-11-10 Issue:2 Volume:99 Page:235-242
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Thomas F¹²,Hennebelle I¹²,Delmas C¹²,Lochon I¹²,Dhelens C³,Garnier Tixidre C⁴,Bonadona A⁵,Penel N⁶,Goncalves A⁷,Delord JP²⁸,Toulas C⁹,Chatelut E¹²

Affiliation:

1. Institut Claudius Regaud, IUCT-O, Department of Pharmacology; Toulouse France

2. EA4553; Univ. Toulouse III Paul Sabatier; Toulouse France

3. UJF Grenoble I, University Hospital Albert Michallon, Department of Pharmacy; Grenoble France

4. Institut Daniel Hollard, Department of Medical Oncology; Grenoble France

5. University Hospital Albert Michallon, Medical Intensive Care Unit, UJF Grenoble I; Grenoble France

6. Centre Oscar Lambret, Department of Medical Oncology; Lille France

7. Institut Paoli Calmettes, Department of Medical Oncology; Marseille France

8. Institut Claudius Regaud, IUCT-O, Department of Medical Oncology; Toulouse France

9. Institut Claudius Regaud, IUCT-O, Laboratory of Oncogenetics; Toulouse France

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference50 articles.

1. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors;Meta-Analysis Group in Cancer;J. Clin. Oncol.,1998

2. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy;Lu;Clin. Cancer Res.,1998

3. Population study of dihydropyrimidine dehydrogenase in cancer patients;Etienne;J. Clin. Oncol.,1994

4. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil;Kuilenburg;Eur. J. Cancer,2004

5. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer;Deenen;Clin. Cancer Res.,2011

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenetics and Adverse Events in the Use of Fluoropyrimidine in a Cohort of Cancer Patients on Standard of Care Treatment in Zimbabwe;Journal of Personalized Medicine;2023-03-28

2. Identification of DPYD variants and estimation of uracil and dihydrouracil in a healthy Indian population;Personalized Medicine;2022-11-23

3. Detection of relevant pharmacogenetic information through exome sequencing in oncology;Pharmacogenomics;2022-09

4. Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population;Frontiers in Pharmacology;2022-06-15

5. Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase;Clinical and Translational Science;2021-12-04